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a  b  s  t  r  a  c  t
Multiple  sclerosis  (MS)  is a chronic  inﬂammatory  demyelinating  disease  leading  to axonal  injury.  Even
if  the  etiology  of  MS  is  still unknown  the  disease  begins  with  inﬂammation  involving  autoreactive  T
lymphocytes  activation  in  genetically  susceptible  subjects.  Interferon  beta-1b  (IFN    1b)  is  one  of  the
most  used  drug  in  the  MS therapy.
The  results  obtained  in  this  study  show  that  the concentration  of  SOD1  in  CSF  of relapsing-remitting
MS  (RR-MS)  patients,  evaluated  by  enzyme-linked  immunosorbent  assay  (ELISA),  is decreased  compared
to  pathological  controls.  Moreover,  the  Western  blotting  analysis  demonstrated  that  SOD1  in  human
peripheral  blood  mononuclear  cells  (PBMC)  in  healthy  controls  was  signiﬁcantly  higher  compared  to  MS
subjects  before  starting  DMT  therapy.  In  addition  IFN   1b therapy  causes  an  increase  of  intracellular
SOD1  protein  as  well  as  mRNA  levels  in  PBMC.  Moreover,  the  treatment  of  neuroblastoma  SK-N-BE  cells
with IFN   1b  increased  SOD1  protein  and  mRNA  levels;  these  data  also  suggest  that  neuroprotective
effect  of this  physiological  molecule  is, at least  in  part,  carried  out through  its effect  on  SOD1.  This  study
demonstrate  that DMT  therapy  is  able  to  increase  SOD1  expression  in PBMC  of  RR-MS  patients.  Therefore,
the  effectiveness  of  DMT  therapy  can  be  ascribed,  at  least  in  part,  to  an  increased  levels  of this  antioxidant
enzyme  as  further  conﬁrmed  by  in  vitro  studies  in  SK-N-BE  cells.
©  2015 Elsevier  Inc.  All  rights  reserved.. IntroductionMultiple sclerosis (MS) is a chronic inﬂammatory demyelinat-
ng disorder of the Central Nervous System (CNS) characterized by
he inﬁltration of CNS white matter by myelin-reactive lymphocyte
Abbreviations: SOD1, superoxide dismutase; MS,  multiple sclerosis; ELISA,
nzyme-linked immunosorbent assay; CSF, cerebrospinal ﬂuid; CNS, central
ervous system; P Ctr, pathological controls; HD, healthy donator; SK-N-BE,
uman neuroblastoma cells; PBMC, peripheral blood mononuclear cells; BFA,
refeldin A; DMT, dimethyltryptamine; IFN, interferon; CDP, chronic inﬂamma-
ory demyelinating polyneuropathy; EAE, autoimmune encephalomyelitis; RR-MS,
elapsing-remitting multiple sclerosis.
∗ Corresponding author. Fax +39 0817463639.
E-mail address: mondola@unina.it (P. Mondola).
ttp://dx.doi.org/10.1016/j.brainresbull.2015.08.009
361-9230/© 2015 Elsevier Inc. All rights reserved.T leading to primary or secondary axonal injury. The etiology of
MS is not yet known; it has been reported that genetic factors
could play important roles in the pathogenesis of this disease (Ebers
and Sadovnick, 1994; Oksenberg et al., 1993; Reboul et al., 2000;
Kantarci et al., 2002; Tolide-Ie et al., 2014). It is also known that
environmental factors, such as smoking (Russo et al., 2011), viral
infections and vitamin D status have been linked to the occurrence
of MS  (De Lorenze et al., 2006; Marrie, 2004).
Although the initiating event of MS  is a matter of debate, the
disease begins with inﬂammation involving autoreactive T lym-
phocytes (Dhib-Jalbut et al., 2002) that could be triggered by viral
infection in genetically susceptible subjects (Marrie, 2004). In addi-
tion, activated monocytes and macrophages can also release a
variety of neurotoxic molecules like nitric oxide, reactive oxy-
gen species (ROS) that contribute to the destruction of the myelin
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Table 1
Demographic and clinical characteristics of patients.
Characteristic RR-MS patients (23) ONID (20) HD (10) p Value
Female, N (%) 18 (78.3) 13 (65) 5 (50) p = 0.26
Age,  mean± SD (years) 32.6 ± 8.9 34.4 ± 8.2 37.6 ± 6.9 p = 0.69
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Fig. 1. SOD1 expression decreases in CSF of MS patients.
Enzyme-linked detection of SOD1 in cerebrospinal ﬂuid of control versus MSDisease duration, mean ± SD (months) 35.82 ± 55.86
EDSS, mean ± SD 2.51 ± 0.58
heath (Dhib-Jalbut et al., 2002). Moreover histological data from
he spinal cord of mice affected by autoimmune encephalomyelitis
EAE), that represents a good experimental animal model of MS,
onﬁrm a strong correlation of inﬂammation and axonal injury
ith perivascular lymphocytes inﬁltration that spread into the
arenchyma (Giuliani and Yong, 2003).
It has been also recently demonstrated that autoimmune pro-
ess affects not only the white matter but also the grey matter in
he course of the disease (Derakhshan et al., 2013).
Many experimental data suggest a signiﬁcant role of ROS in the
athogenesis of myelin destruction in MS  as well as in other neu-
odegenerative diseases. Mitochondria constantly produce ROS,
hich have important signalling functions (Damiano et al., 2012,
015). When the rate of ROS production exceeds the cellular antiox-
dant capacity it can cause oxidative stress and extensive damage
o essential cell components (Lin and Beal, 2006; Witte et al., 2013).
owever so far it is not completely clear whether the correlation
etween ROS and MS  is due to a decrease of enzymatic antioxidant
efence mechanisms or to an overproduction of ROS.
In previous researches we showed that the antioxidant enzyme
u–Zn superoxide dismutase (SOD1) is secreted by many cellu-
ar lines including human neuroblastoma SK-N-BE cells through
 microvesicles pathway (Mondola et al., 2003) and increases cal-
ium intracellular levels through an activation of phospholipase
-protein Kinase C pathway (Mondola et al., 2004, 1996). It has also
een shown that an impaired secretion of mutant superoxide dis-
utase 1 is associated with neurotoxicity in familial amyotrophic
ateral sclerosis (ALS) (Turner et al., 2005; Turner and Atkin, 2006);
oreover an endoplasmic reticulum (ER) stress, associated with
n unfolded protein response and Golgi apparatus fragmentation
n mutant SOD, is present in familial ALS (Mondola et al., 2004).
ecent data demonstrated that SOD1 is able to activate, through
uscarinic M1  receptor, a trasductional pathway involving P-ERK
nd P-AKT in human neuroblastoma SK-N-BE cells (Damiano et al.,
013).
The aim of the present research was to evaluate the SOD1
mount in plasma and cerebrospinal ﬂuid (CSF) of relapsing-
emitting multiple sclerosis (RR-MS) subjects, pathological and
ealty controls; we also evaluated how interferon  1b (IFN) could
odify the expression of SOD1 in neuroblastoma SK-N-BE cells and
n peripheral blood mononuclear cells (PBMC) of RR-MS patients.
A further goal of this study was to investigate whether IFN beta-
b can affect export of SOD1 in neuroblastoma SK-N-BE cells.
. Material and methods
.1. Patients
We  enrolled 23 consecutive outpatients of the MS  Centre of Fed-
rico II University Hospital (Naples Italy), from May to November
010 with clinically deﬁnitive RR-MS according to the Mc Donald
riteria (Polman et al., 2005), aged 20–50 years without relapse nor
orticosteroids treatment in the previous 3 months naïve to any dis-
ase modifying therapy. Patients were treated with 250 g/ml IFN
eta-1b (8.000.000 IU) on alternate days with subcutaneous injec-
ion. Visits were scheduled with monthly neurological evaluation
nd blood samples were collected at baseline and after 3 months ofpatients; the values of SOD1 are expressed as% value. Error bars indicate ±SE
(*P < 0.001). Statistical analysis has been performed by using t-test study.
therapy. Committee approval was obtained and each patient gave
their signed informed consent to participate in this study.
We  also enrolled 20 patients with other neurological inﬂam-
matory disease (ONID) such as LES, Systemic Sclerosis, Vasculitis
and CIDP (Chronic Inﬂammatory Demyelinating Polyneuropathy)
used as pathological controls (P Ctr). Patients and pathological con-
trols were matched by age and gender. CSF was collected from 20
RR-MS patients and from 23 ONID controls. Written informed con-
sent was  obtained from each patient after a detailed explanation
of all procedures. The study was  approved by the “Federico II” Uni-
versity Ethical Committee (No 197/11/E1) and was  conducted in
concordance with the Declaration of Helsinki.
In addition we enrolled 10 healthy donators (HD) to evaluate the
amount of intracellular SOD1 in PBMC. Demographic and clinical
characteristics are summarized in Table 1.
2.2. Blood collection
Blood samples were obtained between 07:00 and 09:00 A.M.
from 23 RR-MS patients and 10 healthy donators. Blood testing was
performed in the morning after a 12-h fast either in patients or in
healthy donators. The samples were centrifuged after collection
at 1500 rpm for 10 min. and cell-free supernatants were stored at
−80 ◦C for further analysis.
2.3. PBMC isolation
PBMC cells were isolated from 12 ml  of blood drawn by vein
puncture from HD and RR-MS patients; diluted (1:1 with PBS) sam-
ples were layered on the top of Ficoll solution (Ficoll-GE Healthcare)
and spun at 3000 rpm for 25 min. PBMC cells were collected, two
time washed in PBS and then spun at 3000 rpm for 4 min; the pellet
fraction was then dissolved in RIPA buffer before polyacrylamide
gel electrophoresis (PAGE) determination.
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Fig. 2. Protein and mRNA SOD1 expression increase in MS patients after Interferon treatment.
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Danel A shows the Western blotting evaluation of SOD1 in PBMC in healthy volunta
n  panel B the different amount of SOD1 in MS patients before and after three mon
OD1  before and after three months of interferon treatment. *P < 0.001 vs HD and v
.4. SOD1 immunoblotting assay of PBMC
Western blotting was performed as previously described
Kantarci et al., 2002). Brieﬂy PBMC cells, washed twice with cold
hosphate-buffered saline were homogenized in buffer contain-
ng 10 mM Tris–HCl, pH 7.4, 4 mM 2-mercaptoethanol, 5 mM EDTA
dding a mix  of protease inhibitors. Nuclei and cell debris were
liminated by slight centrifugation at 3.000 rpm for 5 min; the
upernatant was then centrifuged at 100,000 × g for 1 h at 4 ◦C. After
entrifugation the pellet was discarded and 50 g of total proteins
ere subjected to 10% sodium dodecyl sulfate-polyacrylamide gel
lectrophoresis (SDS-PAGE) under reducing conditions; then the
roteins were transferred onto a nitrocellulose ﬁlter membrane
GE-Healthcare, UK) with a Trans-Blot Cell (Bio-Rad Laboratories,
K) and transfer buffer containing 25 mM Tris, 192 mM glycine,
0% methanol. Membranes were placed in 5% non-fat milk in
hosphate-buffered saline, 0.5% Tween 20 (PBST) at 4 ◦C for 2 h to
lock the non speciﬁc binding sites. Filters were incubated with
peciﬁc antibodies before being washed three times in PBST and
hen incubated with a peroxidase-conjugated secondary antibody
GE-Healthcare, UK). After washing with PBST, peroxidase activity
as detected with the enhanced chemiluminescent (ECL) system
GE-Healthcare, UK).
SOD1 was detected by a rabbit polyclonal antibodies purchased
y Santa Cruz Biotechnology (USA) diluted 1:1000 in 0.1% Tween
0 PBS.The ﬁlters were also probed with an anti -tubulin antibody
Sigma, USA). Protein bands were revealed by ECL and, when
peciﬁed, quantiﬁed by densitometry using Scion Image software.
ensitometric values were normalized to -tubulin.jects (CTR) and in subjects affected by MS before starting the interferon treatment.
interferon treatment is showed. Panel C indicates the semi-quantitative RT-PCR of
 0 (Panel A and B). **P < 0.005 vs Time 0 (Panel C).
2.5. Neuroblastoma SK-N-BE cells culture
Human neuroblastoma SK-N-BE cells (American Type Culture
Collection, ATCC, USA) and were grown in monolayer in RPMI 1640
medium supplemented with 10% FBS, 2 mM l-glutamine, 50 g/ml
streptomycin and 50 IU/ml penicillin. The cells were kept in a 5%
CO2 and 95% air atmosphere at 37◦C. SK-N-BE and grown to semi-
conﬂuence in 60-mm dishes, then were washed twice with PBS and
incubated for 18 h in medium containing 0.2% FBS before the exper-
iments. The cells were then incubated for 3 h with 100.000 U/ml of
IFN  1a in presence of 5 g/ml of the inhibitors of SOD1 protein
secretion Brefeldin A (BFA) and in presence and in absence of 3 l of
20 M DPI. SK-N-BE and cell lysates were obtained in RIPA buffer,
containing 50 mM.
Tris–HCl, pH 7.5, 150 mM NaCl, 1% NP40, 0.5% deoxycholate,
0.1% SDS,2.5 mM Na-pyrophosphate, 1 mM -glycerophosphate,
1 mM NaVO4, 1 mM NaF, 0.5 mM PMSF and a cocktail of protease
inhibitors (Roche, USA). The cells were kept for 15 min  at 4 ◦C and
disrupted by repeated aspiration through a 21-gauge needle. Cell
lysates were centrifuged for 15 min  at 13,000 rpm and the pellets
were discarded. Fifty micrograms of total proteins was  subjected
to SDS-PAGE under reducing conditions.
After electrophoresis, the proteins were transferred onto
a nitrocellulose ﬁlter membrane (GE-Healthcare, UK) with a
Trans-Blot Cell (Bio-Rad Laboratories, UK) and transfer buffer
containing 25 mM Tris, 192 mM glycine, and 20% methanol. Mem-
branes were placed in 5% non-fat milk in tris-buffered saline,
0.1% Tween 20 (TBST) at 4 ◦C for 2 h to block the nonspeciﬁc
binding sites. Filters were incubated with speciﬁc antibodies
before being washed three times in TBST and then incubated
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Fig. 3. SOD1 protein levels determined by ELISA assay increase after interferon treatment in SK-N-BE cells.
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anel  B indicates the value of extracellular SOD1 after the same treatment as indi
refeldin A pretreatment in absence and in presence of DPI is illustrated. *P < 0.005
ith a peroxidase-conjugated secondary antibody (GE-Healthcare,
K).
After washing with TBST, peroxidase activity was  detected with
he ECL system (GE-Healthcare, UK). SOD1 was detected with rab-
it polyclonal antibodies; SOD1 antibodies were from Santa Cruz
iotechnology Inc. (USA), Protein bands were revealed by ECL
nd, when speciﬁed, quantiﬁed by densitometry using ScionIm-
ge software. Densitometric values were normalized to -tubulin
ntibodies. Each experiment was three times repeated.
.6. RNA preparation
Total RNAs of cell lines were extracted with High Pure RNA
solation kit (Roche), according to the manufacturer’s instructions,
sing 2 × 106 cells. Traces of contaminated DNA were removed with
NAse I treatment.
.7. Semi-quantitative RT-PCR
To improve the accuracy and sensitivity of the procedure,
e performed a one-step quantitative reverse transcription poly-
erase chain reaction, in which the reverse transcriptase enzyme
nd a Taq DNA polymerase blend, possessing a proofreading activ-
ty were combined in the one tube, and a single, non-interrupted
hermal cycling program. Quantiﬁcation was achieved in a single
eaction by using the housekeeping beta-actin gene as internal
tandard. 100 ng of RNA template was reverse-transcribed in 50 ll
eaction mix  containing 200 lM dNTPs, 100 mM DTT, 0.25 ll RNase
nhibitor, 1.5 mM MgCl2, and 1 ll enzyme mix  (Titan One-tube RT-
CR kit, Roche). The solution was incubated for 30 min at 50 ◦C in an
utomated DNA thermal cycler (GeneAmp 2400 Perkin.Elmer). To
erform RT-PCR at optimal conditions and to stay within the loga-
ithmically linear product formation, 40 cycles were chosen (30 s at
4 ◦C, 30 s at 59 ◦C, 60 s at 68 ◦C) and were followed by a ﬁnal exten-
ion for 7 min  at 68 ◦C. b-actin, SOD1, primers pairs were designederon treatment in absence and in presence of reactive oxygen species inhibitor DPI.
in Panel A. In Panel C the impairment of interferon-induced SOD1 secretion after
I **P < 0.001 vs control.
to yield PCR products of different sizes, 587 bp for b-actin, 290 bp
for SOD1.
The forward and reverse b-actin primers
were 5′-CC AAGGCCAACCGCGAGAAGATGAC-30, 50-
AGGGTACATGGTGGTGCCGCCAGAC-3′, respectively; the forward
and reverse SOD1 primers were 5′-CAGTGCAG GTCCTCACTTTA-3′
and 5′-CCTGTCTTTGTACTTTCTTC-3′, respectively. To rule out
genomic DNA contamination we  performed a negative control
which contained RNA instead of cDNA. The signal intensities of PCR
products were separated on a 1.2% agarose gel and were visualized
by ethidium bromide staining. The products’ signal intensities
were determined by computerized densitometric analysis using
Fotoplot software. The expression of SOD1 was normalized to
b-actin mRNA levels.
2.8. DNA sequencing
To check the speciﬁcity of the ampliﬁed products, DNA bands
were eluted from the gel and puriﬁed; sequence analysis was
determined by the Big Dye Terminator Cycle Sequencing method
(ABI-PRISM Sequencer 310 PerkinElmer).
2.9. Enzyme-linked immunosorbent assay (ELISA)
The quantitative detection of CuZn superoxide dismutase
(SOD1) in the cerebrospinal ﬂuid was determined by the Bender
Med system kit (Bender Med  System Diagnostic,Vienna, Austria) as
previously described (Mondola et al., 2003). The concentration of
SOD1 on the liquor was  determined in undiluted samples calculat-
ing the average absorbance (450 nm)  values for each sample and
for standard curve in triplicate. The reproducibility of the method
was evaluated in an independent experiment; the detection limit of
the assay was  0.07 ng/ml and the intra-assay coefﬁcient of variation
was 4.8%.
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.10. Statistical analysis
All results shown are mean ± SE of at least three separate exper-
ments. Statistical differences were evaluated using a Student’s t
est; for unpaired samples.
. Results
23 RR-MS patients, 20 age and gender matched ONID patients
nd 10 age and gender matched HD were enrolled.
.1. SOD1 detection in CSF
SOD1 determination in cerebrospinal ﬂuid in 10 pathological
ontrols and in 10 RR-MS patients is shown in Fig. 1. As can be
oticed in RR-MS subjects, a statistical signiﬁcant decrease of SOD1
oncentration (p < 0.001) was observed respect to pathological con-
rols suggesting an impaired secretion of this antioxidant enzyme
n RR-MS patients.
.2. Detection of SOD1 in PBMC
In Fig. 2 (Panel A) the Western blotting analysis of SOD1 in
BMC of voluntary healthy donators (HD) and in RR-MS patients
as shown. As can be noticed, before starting DMT  therapy, the
OD1 protein amount was strongly decreased compared to healthy
onators. EDSS and disease duration were not related to SOD1 level.
IFN beta-1b therapy modiﬁes SOD1 protein levels in PBMC of
R-MS; as shown in Fig. 2, after three months of Interferon  1b
reatment an increase of both intracellular SOD1 (Panel B) protein
nd mRNA (Panel C) levels in PBMC were observed.
.3. Effect of IFN beta-1b in SK-N-BE cells
In Fig. 3 (Panel A) the increase of intracellular SOD1 protein
mount after incubation with 100 ng/ml of IFN beta 1b 3 h is shown.
he effect was not dependent on ROS because the preincubation of
he cells for 15 min  with 20 M DPI, an inhibitor of ROS, did not
mpair interferon effects on SOD1. In addition, in presence of BFA,
hat impairs SOD1 secretion, the export of SOD1 strongly decreases
panel C) suggesting an involvement of BFA on SOD1 export.
The same increase (about 50%) of SOD1 mRNA levels was
bserved in neuroblastoma SK-N-BE cells after incubation with
nterferon  1b (data non shown).
. Discussion
Multiple sclerosis in one of the most common cause of disabil-
ty in young adults, mainly in female subjects. Despite an elevated
umber of studies, the pathogenesis of this disease still remains
bscure. Many studies indicate that the disease risk is more ele-
ated in family members with MS  disease compared to general
opulations (Sadovnick et al., 1997); in addition several epidemi-
logical data indicate that speciﬁc bacteria or virus infections,
ssociated to oxidative stresses, can be involved in this chronic
emyelinating inﬂammation. The imbalance between ROS pro-
uction and antioxidant defense mechanisms are associated to
any neurodegenerative diseases, included MS.  To this respect
he antioxidant superoxide dismutase (SOD) isoenzymes could car-
ied out a key role in the MS  disease. We  previously showed for
he ﬁrst time that CuZn superoxide dismutase (SOD1) is exported
y many cellular lines including human neuroblastoma SK-N-BE
ells (Mondola et al., 2003, 2004). Subsequently, observations from
everal authors also conﬁrmed the presence of SOD1 in cultureh Bulletin 118 (2015) 1–6 5
medium from different cell types (Turner et al., 2005; Urushitani
et al., 2006; Gomes et al., 2007).
In this preliminary study we  evaluated the effect of DMT  ther-
apy for a short period of three months on SOD1 protein amount and
its gene expression in peripheral blood mononuclear cells (PBMC)
of asymptomatic RR-MS patients. We found that after DMT ther-
apy with IFN  1b, intracellular concentration of SOD1 in PMBC
of RR-MS patients increased compared to the basal levels (before
treatment); in addition, likewise raised the mRNA SOD1 levels.
A further goal of our study has been either to investigate, by
in vitro experiments on neuroblastoma SK-N-BE cells, the effects
of IFN  1b on intracellular content and export of SOD1 in order to
point out the role of SOD1 in the effectiveness of IFN  1b treatment.
The in vitro studies on neuroblastoma SK-N-BE cells showed that
IFN  1b, increases SOD1 intracellular amount as well as its secre-
tion indicating that constitutive SOD1 secretion is modulated by
this molecule (Fig. 3).
This effect cannot be ascribed to reactive oxygen species (ROS)
production by IFN  1b treatment because the ROS inhibitor
diphenyleneiodonium-chloride (DPI) did not affected IFN  1b
effects on intracellular and extracellular SOD1 levels. Moreover
IFN  1b treatment did not increase ROS levels measured by 5,6-
carboxy-2‘,7′-dichloroﬂuorescein-diacetate, DCHF-DA, (Molecular
Probes, The Netherlands) (data not shown).
The absence of ROS production in neuronal cells after IFN 
incubation for a short period was also conﬁrmed by others authors
(Alboni et al., 2013).
In CSF the presence of the three SOD isoenzymes has been pre-
viously demonstrated; CuZn–SOD accounts for ∼75% of the SOD
activity, EC-SOD for 25% and Mn-SOD for <5% (Jacobsson et al.,
2001).
The concentration of CuZn–SOD in CSF could be correlated with
the amount of this enzyme in the cytosol of cells in the CNS. In our
study, the higher level of SOD1 detected in cerebrospinal ﬂuid of
control subjects compared to untreated RR-MS patients suggests
an impaired SOD1 secretion that, decreasing antioxidant defences,
could impair neuroimmunoregulatory responses and therefore,
could have a role in the pathogenesis of multiple sclerosis.
Some studies demonstrated the suppression of the
Lipopolysaccharide-induced in vitro production of two proin-
ﬂammatory cytokines, tumor necrosis factor  (TNF) and
interleukin  (IL-1) in subjects receiving spinal manipulative
therapy (SMT) (Teodorczyk-Injeyan et al., 2006). It could be of
interest to further explore the possible effects of SMT  on the
SOD1 and other cellular antioxidant defences in multiple sclerosis
patients.
Therefore, this preliminary study indicates that the effective-
ness of DMT  therapy can be ascribed, at list in part, to an increase
of intracellular SOD1 levels in addition to an induction of its gene
expression that can be ﬁnalized to improve antioxidant defence
mechanisms. Finally our data on SK-N-BE cells pointed out on
a new physiological mechanism involved in neuroprotection by
interferon  1b.
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